"Azetidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D001384
|
| MeSH Number(s) |
D03.383.082.301
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azetidines".
Below are MeSH descriptors whose meaning is more specific than "Azetidines".
This graph shows the total number of publications written about "Azetidines" by people in this website by year, and whether "Azetidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 0 | 3 |
| 2006 | 4 | 0 | 4 |
| 2008 | 3 | 0 | 3 |
| 2009 | 1 | 2 | 3 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azetidines" by people in Profiles.
-
Safety of nontumor necrosis factor-targeted biologics in the COVID-19 pandemic. J Med Virol. 2021 02; 93(2):714-716.
-
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 07; 72(1):58-71.
-
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
-
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861.
-
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 03; 567(7749):521-524.
-
Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study. Future Oncol. 2019 Sep 01; 15(25):2933-2942.
-
Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin Cancer Res. 2017 Sep 01; 23(17):5238-5245.
-
Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol. 2016 Sep-Oct; 10(5):1091-7.
-
Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition. Behav Brain Res. 2016 Mar 15; 301:204-12.
-
Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism. 2015 May; 64(5):633-41.